Program
rapcabtagene autoleucel
Also written as “Rapcabtagene autoleucel”, “rapcabtagene autoleucel (YTB323)” and “YTB323”.
In Novartis's pipeline, CD19 CAR-T
. Its studies are mostly in Lupus Nephritis · Multiple Sclerosis, Chronic Progressive · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Arthritis, Rheumatoid · Scleroderma, Diffuse, led by Novartis.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 87 open or running | phase 2since Feb 27, 2023 | Feb 27, 2023 | Feb 14, 2028phase 2 · NCT06581198 |
- Named in Novartis’s own pipeline as
YTB323 (rapcabtagene autoleucel)
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2023First study: phase 2 study in Lupus Erythematosus, SystemicFirst studyNCT05798117 · 21 enrolled · Australia, France, Germany and more
- Aug 23, 2024Phase 2 study in Lupus Erythematosus, SystemicNCT06581198 · 179 enrolled · United States, Argentina, Australia and more
- Sep 26, 2024Phase 2 study in Multiple SclerosisNCT06617793 · 28 enrolled · Australia, France, Germany and more
- Oct 22, 20242 phase 2 studiesNCT06655896, NCT06665256
- Nov 4, 2024Phase 2 study in Multiple Sclerosis, Chronic ProgressiveNCT06675864 · 28 enrolled · Australia, Canada, France and more
- Mar 7, 2025Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06868290 · 126 enrolled · United States, Brazil, Israel and more
- Jun 24, 2025Phase 2 study in Arthritis, RheumatoidNCT07048197 · 27 enrolled · France, Germany, Singapore and more
Ahead
- Feb 14, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06581198
- Nov 1, 2028Primary completion: phase 2 study in Arthritis, RheumatoidNCT07048197
- Nov 30, 2028Primary completion: phase 2 study in Scleroderma, DiffuseNCT06655896
- Mar 9, 2029Primary completion: phase 2 study in MyositisNCT06665256
TargetBeta
“CD19 CAR-T”the company's pipeline, read by Claude · source
“A preparation of autologous T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, ”NCIt, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07048197Arthritis, Rheumatoid · France, Germany, Singapore and more | 2 | Active, not recruiting | Nov 1, 2028 | 27 |
| NCT06868290Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States, Brazil, Israel and more | 2 | Active, not recruiting | Jun 7, 2029 | 126 |
| NCT06675864Multiple Sclerosis, Chronic Progressive · Australia, Canada, France and more | 2 | Active, not recruiting | Jun 14, 2030 | 28 |
| NCT06665256Myositis · United States, Australia, Brazil and more | 2 | Active, not recruiting | Mar 9, 2029 | 21 |
| NCT06655896Scleroderma, Diffuse · United States, Argentina, Australia and more | 2 | Active, not recruiting | Nov 30, 2028 | 96 |
| NCT06617793Multiple Sclerosis · Australia, France, Germany and more | 2 | Active, not recruiting | Aug 7, 2030 | 28 |
| NCT06581198Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Active, not recruiting | Feb 14, 2028 | 179 |
| NCT05798117Lupus Erythematosus, Systemic · Australia, France, Germany and more | 2 | Completed | Sep 24, 2026 | 21 |
How it is read
Names in the registry
- “Rapcabtagene autoleucel”, 3 entries
- “rapcabtagene autoleucel (YTB323)”, 2 entries
- “rapcabtagene autoleucel”, 2 entries
- “YTB323”, 1 entry
Conditions, from the studies’ own filings
- Lupus Nephritis, 2 studies
- Multiple Sclerosis, Chronic Progressive, 1 study
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, 1 study
- Arthritis, Rheumatoid, 1 study
- Scleroderma, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.